The high-performance personalized minimal residual disease (MRD) and recurrence test with exceptional sensitivity and specificity

RaDaR has been carefully designed to help you detect tumor DNA in the blood with exceptional sensitivity and specificity

  • Increased accuracy with a tumor-informed, personalized panel design: RaDaR sequencing assays monitor up to 48 tumor-specific mutations, unique to each patient’s tumor, to help detect circulating tumor DNA (ctDNA)
  • Earlier detection with high sensitivity: RaDaR can detect extremely low levels of ctDNA in the blood, with a demonstrated LoD95 = 0.001% VAF. This can give additional time for important treatment management decisions
  • Fewer false positives with high specificity: RaDaR has a demonstrated analytical specificity of 100% in validation studies, giving you the confidence that comes from having more reliable results

NeoGenomics has been supporting oncologists and pathologists in their goal to provide patients with the best care possible since 2002.

LoD95 = limit of detection, working at a confidence of 95%; VAF = variant allele fraction.

tumor informed approach

A tumor-informed approach, unique and personalized to each patient

RaDaR begins with whole-exome sequencing (WES), which is performed on an individual’s tumor sample to identify mutations specific to that patient. Next, personalized RaDaR next-generation sequencing (NGS) assay panels are designed for each patient based on the mutations identified in their tumor sample.

Enhanced accuracy
Age-related somatic mutations in hematopoietic progenitor cells – known as clonal hematopoiesis of indeterminate potential (CHIP) – can lead to false-positive plasma genotyping.

  • RaDaR incorporates comprehensive quality control (QC) throughout the workflow, such as the deep sequencing of buffy coat DNA
  • This process optimizes MRD specificity and allows for the identification and removal of CHIP or germline mutations 
  • This ensures that variants are derived from the tumor and not from other sources

RaDaR results are analyzed using an aggregated algorithmic approach to determine MRD results, further reducing false positive results.

RaDaR’s exceptional sensitivity (LoD95 = 0.001% VAF) and specificity (100%) minimize the risks of false-negative ctDNA detection and help ensure that patients receive the right treatment plan for their individual needs.

The RaDaR workflow has five fundamental steps

A patient’s surgically resected tumor or biopsy sample undergoes whole-exome sequencing (WES) to identify tumor-specific variants.
A group of up to 48 variants are then selected using optimized algorithms. An assay targeting these mutations is customized to generate a personalized RaDaR panel.
Using the InVision® platform and the personalized assay, partition-based multiplex PCR (polymerase chain reaction) is performed. This generates sequencing libraries from the patient’s plasma cell-free DNA (cfDNA), tumor DNA and leukocyte DNA for the targeted regions.
The patient’s plasma cfDNA and leukocyte DNA (from blood buffy coat) are now sequenced at a high depth. Tumor DNA is also sequenced to confirm the variants are tumor-specific. Leukocyte DNA high-depth sequencing allows for the identification and removal of germline changes and confounding signals derived from clonal hematopoiesis of indeterminate potential (CHIP) (which may be present in the blood at low levels) from the analysis. This final process reduces false-positive results and contributes to high specificity and a high positive predictive value (PPV).
NGS data are analyzed by combining results across all tumor-specific variants to determine the patient’s MRD status. A report is then generated indicating whether tumor DNA was “Detected” or “Not Detected” in the patient’s blood samples.

With your patient’s personalized assay panel, sample analysis turnaround time is seven calendar days


RaDaR assay design and development

Tissue specimen
Ten sections of 10 μm formalin-fixed
paraffin-embedded tumor tissue excised from patient

4 weeks

Plasma cfDNA analysis for MRD monitoring

Blood sample
2 x 10 mL blood draw

7 days

ctDNA = circulating tumor DNA; LoD95 = limit of detection, working at a confidence of 95%; VAF = variant allele fraction.

How to order a RaDaR test


NeoGenomics prides itself on its unparalleled customer support team. If you have questions regarding test information, specimen requirements, turnaround times, test add-on, and test results, please feel free to reach out to a Client Services Advocate at client.services@neogenomics.com or call 866.776.5907, option 3.


Online Ordering streamlines and simplifies your test-ordering process into a single time-saving, easy-to-use experience.


Complete a RaDaR test requisition form.

New to NeoGenomics? Call the NeoGenomics Client Services team at 866.776.5907 and press 3 to set up an account.

RaDaR MRD testing is validated for use in multiple solid tumor cancers





Get started with RaDaR

Contact us to order a RaDaR test.

Zip Code